Full Text View
Tabular View
No Study Results Posted
Related Studies
Functional and Clinical Long-Term Outcome of Ewing Sarcoma Treatment
This study is not yet open for participant recruitment.
Verified by University Hospital Muenster, January 2009
First Received: January 15, 2009   No Changes Posted
Sponsors and Collaborators: University Hospital Muenster
German Federal Ministry of Education and Research
Information provided by: University Hospital Muenster
ClinicalTrials.gov Identifier: NCT00824083
  Purpose

The purpose of the study is to assess the functional outcome, quality of life and late sequelae in a representative sample of 1100 long-term survivors of Ewing sarcoma and to build a unique clinical and functional data pool of the underlying cohort of 3000 Ewing sarcoma patients with a follow-up of 3 decades.


Condition
Sarcoma, Ewing's

MedlinePlus related topics: Soft Tissue Sarcoma
U.S. FDA Resources
Study Type: Observational
Study Design: Cohort, Prospective
Official Title: Functional and Clinical Long-Term Outcome of Ewing Sarcoma Treatment

Further study details as provided by University Hospital Muenster:

Primary Outcome Measures:
  • real-world daily activity (SAM: step-activity-monitor) [ Time Frame: 5-30years after primary diagnosis of Ewing sarcoma ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • health-related quality of life (SF36, PEDQOL) [ Time Frame: 5-30years after primary diagnosis of Ewing sarcoma ] [ Designated as safety issue: No ]
  • functional status (TESS) [ Time Frame: 5-30years after primary diagnosis of Ewing sarcoma ] [ Designated as safety issue: No ]
  • psychological status (HADS, BIS-BAS) [ Time Frame: 5-30years after primary diagnosis of Ewing sarcoma ] [ Designated as safety issue: No ]

Biospecimen Retention:   None Retained

Biospecimen Description:

Estimated Enrollment: 2200
Study Start Date: July 2009
Estimated Study Completion Date: July 2014
Groups/Cohorts
1
sarcoma survivors
2
healthy subjects

Detailed Description:

Trial objective: As survival rates of bone sarcoma patients have been raised owing to improved treatment strategies the focus of investigations is now on the medical, social, and economic sequelae of intensive multimodal treatment. This study aims to assess the functional outcome, quality of life and late sequelae in a representative sample of long-term survivors of Ewing sarcoma. The data recorded combined with standardized treatment data covering a 30-year period will produce a data pool that is unique for its magnitude and will be used for the development of guidelines for further improvements of future bone sarcoma treatment.

Working plan: The working plan provides for the assessment of functional outcome and quality of life by means of validated tools (TESS, SF36, PEDQOL) and objectively measuring daily activity patterns by using the Step Activity Monitor (SAM) in 1100 long-term Ewing sarcoma survivors and a control group of 1100 matched healthy subjects. Information on sarcoma treatment and follow-up is obtained by re-structuring and complementing the database of the relevant patient cohort (n=3000) from four consecutive nationwide and international clinical trials between 1980 and 2008. Procedures of local treatment will be evaluated regarding functional outcome, quality of life, and survival probability and prognostic factors predicting long-term outcome will be identified.

Exploitation of results: The results will be presented at scientific meetings and will be published in international journals. Guidelines will be developed regarding improvements in the treatment, rehabilitation, and social integration of bone sarcoma patients to be utilized in guiding patients and in the decision process of medical professionals regarding their treatment. In the long run, the evidence based guidelines on treatment and follow-up are to be transferred into the health system.

  Eligibility

Ages Eligible for Study:   6 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Ewing sarcoma survivors and 1:1 matched control group of healthy subjects

Criteria

Inclusion Criteria:

  • CESS81/CESS86/EICESS92/EURO-E.W.I.N.G.99 trials participants of the German Society of Pediatric Hematology and Oncology (GPOH)

Exclusion Criteria:

  • no complete remission (CR)
  • any kind of paralysis
  • <5y after diagnosis
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00824083

Contacts
Contact: Andreas Ranft, Dr. 0049-251-8356486 andreas.ranft@ukmuenster.de
Contact: Christiane Hoffmann, Dr. 0049-251-8356485 Christiane.Hoffmann@ukmuenster.de

Locations
Germany, North Rhine Westphalia
Department of Pediatric Hematology and Oncology, University Children's Hospital
Muenster, North Rhine Westphalia, Germany, 48129
Motion Analysis Lab, Orthopedic Department, University Hospital
Münster, North Rhine Westphalia, Germany, 48129
Sponsors and Collaborators
University Hospital Muenster
German Federal Ministry of Education and Research
Investigators
Principal Investigator: Heribert Jürgens, Prof. University Hospital Muenster
Principal Investigator: Dieter Rosenbaum, Prof. University Hospital Muenster
  More Information

Publications:
Brandes M, Schomaker R, Möllenhoff G, Rosenbaum D. Quantity versus quality of gait and quality of life in patients with osteoarthritis. Gait Posture. 2008 Jul;28(1):74-9. Epub 2007 Nov 28.
Gerber LH, Hoffman K, Chaudhry U, Augustine E, Parks R, Bernad M, Mackall C, Steinberg S, Mansky P. Functional outcomes and life satisfaction in long-term survivors of pediatric sarcomas. Arch Phys Med Rehabil. 2006 Dec;87(12):1611-7.
Hoffmann C, Gosheger G, Gebert C, Jürgens H, Winkelmann W. Functional results and quality of life after treatment of pelvic sarcomas involving the acetabulum. J Bone Joint Surg Am. 2006 Mar;88(3):575-82.
McDonald CM, Widman L, Abresch RT, Walsh SA, Walsh DD. Utility of a step activity monitor for the measurement of daily ambulatory activity in children. Arch Phys Med Rehabil. 2005 Apr;86(4):793-801.
Nagarajan R, Neglia JP, Clohisy DR, Robison LL. Limb salvage and amputation in survivors of pediatric lower-extremity bone tumors: what are the long-term implications? J Clin Oncol. 2002 Nov 15;20(22):4493-501. Review.
Paulussen M, Craft AW, Lewis I, Hackshaw A, Douglas C, Dunst J, Schuck A, Winkelmann W, Köhler G, Poremba C, Zoubek A, Ladenstein R, van den Berg H, Hunold A, Cassoni A, Spooner D, Grimer R, Whelan J, McTiernan A, Jürgens H; European Intergroup Cooperative Ewing's Sarcoma Study-92. Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol. 2008 Sep 20;26(27):4385-93.
Pieper S, Ranft A, Braun-Munzinger G, Jurgens H, Paulussen M, Dirksen U. Ewing's tumors over the age of 40: a retrospective analysis of 47 patients treated according to the International Clinical Trials EICESS 92 and EURO-E.W.I.N.G. 99. Onkologie. 2008 Dec;31(12):657-63. Epub 2008 Nov 20.
Rödl RW, Hoffmann C, Gosheger G, Leidinger B, Jürgens H, Winkelmann W. Ewing's sarcoma of the pelvis: combined surgery and radiotherapy treatment. J Surg Oncol. 2003 Jul;83(3):154-60.
Rosenbaum D, Brandes M, Hardes J, Gosheger G, Rödl R. Physical activity levels after limb salvage surgery are not related to clinical scores-objective activity assessment in 22 patients after malignant bone tumor treatment with modular prostheses. J Surg Oncol. 2008 Aug 1;98(2):97-100.
Schuck A, Ahrens S, Paulussen M, Kuhlen M, Könemann S, Rübe C, Winkelmann W, Kotz R, Dunst J, Willich N, Jürgens H. Local therapy in localized Ewing tumors: results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials. Int J Radiat Oncol Biol Phys. 2003 Jan 1;55(1):168-77.
Song KM, Bjornson KF, Cappello T, Coleman K. Use of the StepWatch activity monitor for characterization of normal activity levels of children. J Pediatr Orthop. 2006 Mar-Apr;26(2):245-9.
Weddington WW. Psychological outcomes in survivors of extremity sarcomas following amputation or limb-sparing surgery. Cancer Treat Res. 1991;56:53-60. Review. No abstract available.

Responsible Party: University Hospital Muenster ( Prof. Heribert Jürgens )
Study ID Numbers: 01ER0807
Study First Received: January 15, 2009
Last Updated: January 15, 2009
ClinicalTrials.gov Identifier: NCT00824083     History of Changes
Health Authority: Germany: Ethics Commission;   Germany: Federal Ministry of Education and Research

Keywords provided by University Hospital Muenster:
bone tumors
long-term function
daily activity
late sequelae

Study placed in the following topic categories:
Neoplasms, Connective and Soft Tissue
Soft Tissue Sarcomas
Malignant Mesenchymal Tumor
Sarcoma, Ewing's
Bone Neoplasms
Sarcoma
Osteogenic Sarcoma
Osteosarcoma
Ewing's Family of Tumors
Ewing's Sarcoma

Additional relevant MeSH terms:
Neoplasms, Connective and Soft Tissue
Neoplasms
Sarcoma, Ewing's
Neoplasms by Histologic Type
Neoplasms, Bone Tissue
Sarcoma
Osteosarcoma
Neoplasms, Connective Tissue

ClinicalTrials.gov processed this record on May 07, 2009